Skip to contentG
Gilead Sciences, Inc.
G
GILDGilead Sciences, Inc. Source filing unavailable
Q2 2014 · —
Revenue$6.54B$6.54B+136.1% vs Q2 2013 Net Income$3.66B$3.66B+373.0% vs Q2 2013 EPS Diluted$2.20$2.20+378.3% vs Q2 2013 Gross Profit$5,488,000,000+178.2% Operating Income$4,412,000,000+282.4% Operating Cash Flowderived
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gilead Sciences, Inc. · CIK 882095 · Engraved from SEC EDGAR
Free Cash Flowderived$4,094,000,000+351.0% Margins · derivedGross margin84.0%+12.7 pt vs Q2 2013
Operating margin67.5%+25.8 pt vs Q2 2013
Net margin55.9%+28.0 pt vs Q2 2013